Acute Myeloid Leukemia Clinical Trials in Atlanta, Georgia

17 studies are recruiting for acute myeloid leukemia in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

   This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and …

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia

   Locations

   206 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04293562 on ClinicalTrials.gov

2. A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

   Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, …

   Stage

   Phase 1

   Ages

   0 and older

   Site

   Emory Winship Cancer Institute, Atlanta, Georgia

   Locations

   57 in total

   Run by

   Syndax Pharmaceuticals

   See if you can join NCT04065399 on ClinicalTrials.gov

3. A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

   Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Winship Cancer Institute of Emory University /ID# 279006, Atlanta, Georgia

   Locations

   28 in total

   Run by

   AbbVie

   See if you can join NCT07581002 on ClinicalTrials.gov

4. Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

   This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound found in fruits and vegetables. Xylitol has been shown to limit …

   Stage

   Phase 3

   Ages

   1 to 25

   Site

   Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia

   Locations

   39 in total

   Run by

   Children's Oncology Group

   See if you can join NCT07022678 on ClinicalTrials.gov

5. Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

   The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   US-Atlanta GA-EMORY, Atlanta, Georgia

   Locations

   82 in total

   Run by

   Stichting Hemato-Oncologie voor Volwassenen Nederland

   See if you can join NCT07223814 on ClinicalTrials.gov

6. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

   This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide informat…

   Stage

   Phase 1

   Ages

   Up to 22

   Site

   Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia

   Locations

   184 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT04726241 on ClinicalTrials.gov

7. Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

   A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or…

   Stage

   Phase 3

   Ages

   0 to 21

   Site

   Children's Healthcare of Atlanta, Atlanta, Georgia

   Locations

   90 in total

   Run by

   PedAL BCU, LLC

   See if you can join NCT05183035 on ClinicalTrials.gov

8. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory Healthcare - The Emory Clinic, Atlanta, Georgia

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

9. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

   This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cel…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Northside Hospital, Atlanta, Georgia

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07020533 on ClinicalTrials.gov

10. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

    This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

    Stage

    Phase 1

    Ages

    12 to 78

    Site

    Emory University, Atlanta, Georgia

    Locations

    12 in total

    Run by

    Orca Biosystems, Inc.

    See if you can join NCT03802695 on ClinicalTrials.gov

11. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory Winship Cancer Institute, Atlanta, Georgia

    Locations

    39 in total

    Run by

    CellCentric Ltd.

    See if you can join NCT04068597 on ClinicalTrials.gov

12. Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

    This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

    Locations

    22 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT06484062 on ClinicalTrials.gov

13. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Emory - Winship Cancer Institute, Atlanta, Georgia

    Locations

    71 in total

    Run by

    Taiho Oncology, Inc.

    See if you can join NCT04256317 on ClinicalTrials.gov

14. Pilot Imaging Study of Leukemia

    This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other trea…

    Stage

    Phase 1

    Ages

    4 to 80

    Site

    Emory University, Atlanta, Georgia

    Locations

    3 in total

    Run by

    University of Oklahoma

    See if you can join NCT03633955 on ClinicalTrials.gov

15. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in pat…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Emory Healthcare - The Emory Clinic, Atlanta, Georgia

    Locations

    44 in total

    Run by

    Kura Oncology, Inc.

    See if you can join NCT05735184 on ClinicalTrials.gov

16. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Northside Hospital, Atlanta, Georgia

    Locations

    3 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06059391 on ClinicalTrials.gov

17. Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

    This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Emory University - WINSHIP Cancer Center, Atlanta, Georgia

    Locations

    3 in total

    Run by

    Meryx, Inc.

    See if you can join NCT04872478 on ClinicalTrials.gov